Sucampo Pharmaceuticals Inc., of Bethesda, Md., said Health Canada has accepted its new drug submission for Amitiza (lubiprostone), 24 mcg capsules, for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain.